Login / Signup

In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates.

Ali Rezaei-MatehkolaeiSadegh KhodavaisyMohamad Mahdi AlshahniTakashi TamuraKazuo SatohMahdi AbastabarGholam Reza ShokoohiBahram AhmadiMohammad KordSimin TaghipourKoichi MakimuraHamid Badali
Published in: Antimicrobial agents and chemotherapy (2018)
The objective of this study was to assess the in vitro activity of the novel triazole antifungal drug, efinaconazole, and five comparators (luliconazole, lanoconazole, terbinafine, itraconazole, and fluconazole) against a large collection of Trichophyton interdigitale and Trichophyton rubrum clinical isolates. The geometric mean MICs were the lowest for luliconazole (0.0005 μg/ml), followed by lanoconazole (0.002 μg/ml), efinaconazole (0.007 μg/ml), terbinafine (0.011 μg/ml), itraconazole (0.095 μg/ml), and fluconazole (12.77 μg/ml). It appears that efinaconazole, lanoconazole, and luliconazole are promising candidates for the treatment of dermatophytosis due to T. interdigitale and T. rubrum.
Keyphrases
  • candida albicans
  • emergency department
  • combination therapy
  • replacement therapy